News Center
Recently, Moxifloxacin Hydrochloride Tablets (National Drug Approval No. H20264233), developed and held by our wholly-owned subsidiary Chongqing Saintsun Pharmaceutical Technology Co., Ltd., have been officially approved for marketing by the National Medical Products Administration (NMPA). Moxifloxacin Hydrochloride Tablets represent another approved antibiotic product following Tigecycline for Injection and Moxifloxacin Hydrochloride and Sodium Chloride Injection.
Copyright(C)2024,Beijing Lunarsun Pharmaceutical Co.,Ltd. All Rights Reserved. Supported by ChemNet ChinaChemNet Toocle 31fabu Copyright Notice